EUVIMEDEUVIMED entdecken
Open Access

NF1 mutation-driven neuronal hyperexcitability sets a threshold for tumorigenesis and therapeutic targeting of murine optic glioma

Corina Anastasaki, Jit Chatterjee, Joshua P Koleske, Yunqing Gao, Stephanie L Bozeman, Chloe M Kernan, Lara I Marco Y Marquez, Ji-Kang Chen, Caitlin E Kelly, Connor J Blair, Dennis J Dietzen, Robert A Kesterson und 1 weitere

Neuro-Oncology · 2024

DOI: 10.1093/neuonc/noae054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Corina Anastasaki und 12 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Lamotrigine, Optic Nerve Glioma. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Giorgio Foundation, NEI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

With the recognition that noncancerous cells function as critical regulators of brain tumor growth, we recently demonstrated that neurons drive low-grade glioma initiation and progression. Using mouse models of neurofibromatosis type 1 (NF1)-associated optic pathway glioma (OPG), we showed that Nf1 mutation induces neuronal hyperexcitability and midkine expression, which activates an immune axis to support tumor growth, such that high-dose lamotrigine treatment reduces Nf1-OPG proliferation. Herein, we execute a series of complementary experiments to address several key knowledge gaps relevant to future clinical translation.

Methods

We leverage a collection of Nf1-mutant mice that spontaneously develop OPGs to alter both germline and retinal neuron-specific midkine expression. Nf1-mutant mice harboring several different NF1 patient-derived germline mutations were employed to evaluate neuronal excitability and midkine expression. Two distinct Nf1-OPG preclinical mouse models were used to assess lamotrigine effects on tumor progression and growth in vivo.

Results

We establish that neuronal midkine is both necessary and sufficient for Nf1-OPG growth, demonstrating an obligate relationship between germline Nf1 mutation, neuronal excitability, midkine production, and Nf1-OPG proliferation. We show anti-epileptic drug (lamotrigine) specificity in suppressing neuronal midkine production. Relevant to clinical translation, lamotrigine prevents Nf1-OPG progression and suppresses the growth of existing tumors for months following drug cessation. Importantly, lamotrigine abrogates tumor growth in two Nf1-OPG strains using pediatric epilepsy clinical dosing.

Conclusions

Together, these findings establish midkine and neuronal hyperexcitability as targetable drivers of Nf1-OPG growth and support the use of lamotrigine as a potential chemoprevention or chemotherapy agent for children with NF1-OPG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LamotrigineOptic Nerve GliomaAnimalsHumansMiceCarcinogenesisCell ProliferationDisease Models, AnimalMice, TransgenicMidkineMutationNeurofibromatosis 1Neurofibromin 1Neurons

Stichwörter der Autor:innen

NF1lamotriginemidkineneuronal excitabilityoptic glioma

Substanzen

LamotrigineMidkineNeurofibromin 1Nf1 protein, mouse

Autor:innen und Institutionen

  • Departments of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana, USA.

ORCID-Profile: David H Gutmann

Förderung

  • NCI NIH HHS
  • Giorgio Foundation
  • NEI NIH HHS
  • Washington University Genome Engineering
  • Cancer Center Support
  • Gilbert Family Foundation
  • NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Anastasaki, C., Chatterjee, J., Koleske, J. P., Gao, Y., Bozeman, S. L., Kernan, C. M., Marco Y Marquez, L. I., Chen, J. K., Kelly, C. E., Blair, C. J., Dietzen, D. J., Kesterson, R. A., & Gutmann, D. H. (2024). NF1 mutation-driven neuronal hyperexcitability sets a threshold for tumorigenesis and therapeutic targeting of murine optic glioma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae054

Vancouver

Anastasaki C, Chatterjee J, Koleske JP, Gao Y, Bozeman SL, Kernan CM, et al. NF1 mutation-driven neuronal hyperexcitability sets a threshold for tumorigenesis and therapeutic targeting of murine optic glioma. Neuro-Oncology. 2024. doi:10.1093/neuonc/noae054

BibTeX
@article{Anastasaki2024,
  author = {Anastasaki, Corina and Chatterjee, Jit and Koleske, Joshua P and Gao, Yunqing and Bozeman, Stephanie L and Kernan, Chloe M and Marco Y Marquez, Lara I and Chen, Ji-Kang and Kelly, Caitlin E and Blair, Connor J and Dietzen, Dennis J and Kesterson, Robert A and Gutmann, David H},
  title = {NF1 mutation-driven neuronal hyperexcitability sets a threshold for tumorigenesis and therapeutic targeting of murine optic glioma},
  journal = {Neuro-Oncology},
  year = {2024},
  doi = {10.1093/neuonc/noae054}
}
Kostenlos starten →